Corbus Pharmaceuticals

CRBP

Market cap $188M

10.59 USD

+0.45

4.44%

At close Updated Apr 17, 4:00 PM EDT

Pre-market

After hours

10.80

+0.21

1.98%

1 day

4.44%

5 days

8.06%

1 month

9.97%

3 months

23.28%

6 months

-45.19%

Year to date

34.56%

1 year

75.62%

5 years

-78.48%

10 years

-84.38%

About: Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 36

Healthcare Biotechnology